In a report published Monday, Oppenheimer analysts maintained a Perform rating on BioCryst Pharmaceuticals, Inc. BCRX, saying that clinical data could drive the stock higher in 2H15.
BioCryst reported its 1Q15 revenue and EPS at $6.8M and ($0.21), as compared to the Oppenheimer estimates of $3.2M and ($0.26), respectively.
In the report Oppenheimer noted the upcoming milestones for BioCryst as:
- Phase 1a PK/PD/safety data from BCX7353 in 3Q15
- Phase 2b data from BCX4161 (OPuS-2 trial) in 4Q15
- Initiation of a Phase 1b proof-of-concept trial of BCX7353 in 4Q15
"We reiterate our Perform rating on BCRX fundamentals, but see opportunity for share price appreciation in 2H15," the analysts said, citing the "large valuation gap" to competitor Dyax Corp. DYAX and "in anticipation of BCX7353 and BCX4161 readouts in 3Q and 4Q15, respectively."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
